Sentences with phrase «generic pharmaceutical manufacturers»

For the last two decades, the FTC has sought to use antitrust enforcement to stop «reverse payments» between branded and generic pharmaceutical manufacturers.

Not exact matches

Given rising competition in the generics space, Teva could also use the additional size to gain back market share from Indian manufacturers such as Sun Pharmaceuticals.

According to the GAO report, 71 percent of all generic injectable cancer drugs sold in 2008 were produced by just three manufacturers, while 91 percent of the market share of injectable nutrients and supplements was held by just three pharmaceutical firms.

* Eliminate «pay - for - delay» strategies in which a pharmaceutical company with a brand name drug shares profits on that drug with a generic drug manufacturer for the remainder of a patent period, effectively eliminating a patent challenge and competition.

In cases involving the Hatch - Waxman Act and issues involving the expiration of pharmaceutical patents and competition between branded drug companies and generic manufacturers, our antitrust litigation graphics can illuminate a complicated industry and a complex regulatory scheme as below:

Pay - for - delay («PFD») agreements are agreements that are intended to delay the market entry of generic manufacturers with generic drugs in exchange for payments made by original pharmaceutical producers (i.e., holders of patents for an original branded drug).

The TPP requires parties to provide a «pre-approval» procedure for patented pharmaceuticals, with two options: 1) provide notice to a patent holder if a competitor applies to market an identical or similar drug during the patent term, along with an opportunity to seek a legal remedy such as a preliminary injunction before the generic drug is marketed; or 2) preclude marketing approval for a drug that is subject to another person's patent, unless the patent holder or original drug manufacturer consents.

Paul, Weiss client Nichi - Iko Pharmaceutical Co., Ltd., the largest generic drug manufacturer in Japan by sales, announced that it has agreed to acquire Sagent Pharmaceuticals, Inc. in an all - cash tender offer followed by a second - step cash merger, for a total consideration of approximately $ 736 million.

Thankur alleges that the generic drug manufacturer committed Medicare / Medicaid fraud and pharmaceutical fraud.

The Applicant («Teva») was a large manufacturer of generic pharmaceuticals.

Established in 2002, Amneal Pharmaceuticals is a manufacturer of generic pPharmaceuticals is a manufacturer of generic pharmaceuticalspharmaceuticals.